A method of collecting plasma includes receiving donor parameters at a controller of a plasma collection device electronically from a donor management system. The method includes storing a target volume for raw plasma which is based at least in part on donor height and weight used to calculate total donor blood volume, the target volume for raw plasma based on the total donor blood volume. The method includes setting the target volume for raw plasma and controlling the plasma collection device to operate draw and return phases to withdraw whole blood from a donor and separate the whole blood into the plasma product and a second blood component comprising red blood cells and to return the second blood component to the donor. The controller operates the draw and return phases until a volume of raw plasma in the collection container equals the target volume of raw plasma.

A system and a method facilitate the extracorporeal inactivation of pathogens of blood products. The system includes an input peristaltic pump, at least one apheresis device, at least one plasma-treating system, and an output peristaltic pump. The input peristaltic pump, the apheresis device, the plasma-treating system, and the output peristaltic pump are in fluid communication with each other. The plasma-treating system includes at least one primary ultraviolet light (UVL) device, at least one heating device, and at least one cooling device. The input peristaltic pump facilitates the flow of blood from a patient through the system. The apheresis device facilitates separating of plasma from one or more blood cells. The plasma-treating system heats the plasma, inactivates pathogens within the plasma, and then cools the plasma. The output peristaltic pump facilitates the flow of blood from the system and back to the patient.

A device for extracting plasma from a fluid collection tube comprising: a tubular barrel having sidewall surrounding a lumen which extends between proximal and distal ends thereof, the tubular barrel forming a tip at a distal end; a barrel seal movingly seated within the lumen of the tubular barrel, the barrel seal closing and sealing the proximal end of the tubular barrel; a tube seal having a proximal end, a distal end, and a lumen extending therebetween, the proximal end having a frustoconical or chamfered face, the tube seal having an outer diameter sized to sealingly engage with an inner surface of the fluid collection tube, and an inner diameter sized to sealingly engage with an outer surface of the tip of the tubular barrel, the tube seal mounted on the tubular barrel such that the tip of the tubular barrel extends into the tube seal lumen.

The invention provides apheresis devices and their use for removal of substantially all types of cell free DNA (cfDNA) in patients' blood, including nucleosome-bound cfDNA, exosome-bound cfDNA and unbound cfDNA (including double stranded DNA (dsDNA), single stranded DNA (ssDNA) and oligonucleotides), to limit the negative effects of the circulating cfDNA and to treat various diseases.

Described are embodiments that include methods and devices for separating components from multi-component fluids. Embodiments may involve use of separation vessels and movement of components into and out of separation vessels through ports. Embodiments may involve the separation of plasma from whole blood. Also described are embodiments that include methods and devices for positioning portions, e.g., loops, of disposables in medical devices. Embodiments may involve use of surfaces for automatically guiding loops to position them into a predetermined position.

Systems and methods for performing online extracorporeal photopheresis of mononuclear cells are disclosed. During a mononuclear cell collection cycle, blood is removed from a source and separated into a plasma constituent, a mononuclear cell-containing layer, and red blood cells, followed by the collection of a pre-product including at least a portion of the mononuclear cell-containing layer and at least a portion of the separated red blood cells. The mononuclear cell collection cycle may be repeated, followed by the production of a single mononuclear cell product using the collected pre-product(s). The mononuclear cell product is irradiated using a fixed dose of light, such that the mononuclear cell product is produced so as to have a predetermined volume and a predetermined hematocrit, regardless of the number of pre-products used to produce the mononuclear cell product. Following irradiation, at least a portion of the irradiated mononuclear cell product is returned to the source.

The present invention relates to: a combination therapy and a combination product that are for the mobilization of a large amount of hematopoietic stem cells in blood and include substance-P and AMD3100 or a pharmaceutically acceptable salt thereof; a method for collecting a large amount of mobilized hematopoietic stem cells, the method comprising a step for isolating a blood fraction containing the mobilized hematopoietic stem cells from peripheral blood obtained from an individual sequentially administered with substance P and AMD3100 or a pharmaceutically acceptable salt thereof; and a use of a combined product containing substance P and AMD3100 or a pharmaceutically acceptable salt thereof for the mobilization of a large amount of hematopoietic stem cells in blood.

A column for removal of a component from a fluid is disclosed. The column has a compartment with a cross sectional area. The compartment contains beads having a diameter. A ligand selected to bind to the component is coupled to the beads. The cross-sectional area and bead diameter are selected to maintain a flow velocity of the fluid within the compartment below a first threshold, thereby reducing leaching of the ligand into the fluid. Also described herein is an adsorbent comprising a ligand that is attached to a substrate by an amine bond, wherein the ligand is resistant to dissociation from the substrate.

A blood filtration device comprising a generally cylindrical housing having an interior wall. An interior member is mounted interior of the housing and comprises an outer surface having a porous membrane disposed thereon. The housing and interior member are relatively rotatable and define an annular gap therebetween. The blood filtration device also comprises an inlet for directing fluid into the annular gap, a first outlet for exiting filtrate passing through the membrane, and a second outlet for directing from the annular gap the remaining retentate. The porous membrane comprises a first layer and a second layer.

A device for separating blood plasma from whole blood includes a first reservoir and a second reservoir. The first reservoir is configured to receive a sample of whole blood including red blood cells and includes a collection region and a constricted region. The second reservoir is fluidically connected to the constricted region of the first reservoir, such that, responsive to centrifugal force applied to the device, the sample of whole blood disposed within the first reservoir separates into a first fraction and a second fraction. The first fraction is located in the collection region and includes blood plasma from which substantially all red blood cells have been removed. The second fraction is located in the second reservoir and includes blood plasma and red blood cells that have been removed from the first fraction by the centrifugal force. The constricted region inhibits the second fraction from entering the collection region.